预约演示
更新于：2025-06-25
Dotinurad
多替诺雷
更新于：2025-06-25
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H9Cl2NO4S |
InChIKeyVOFLAIHEELWYGO-UHFFFAOYSA-N |
CAS号1285572-51-1 |
关联
30
项与 多替诺雷 相关的临床试验NCT06834230
Effect of Dotinurad in Hyperuricemia with Hypertension: a Randomized Study with Febuxostat (DIANA-NEXT)
JPRN-UMIN000054142
Clinical Study on Dotinurad for Hyperuricemia - Clinical Study on Dotinurad for Hyperuricemia
JPRN-UMIN000054141
Clinical Study on Additional Treatment of Hyperuricemia with Dotinurad - Clinical Study on Additional Treatment of Hyperuricemia with Dotinurad
100 项与 多替诺雷 相关的临床结果
登录后查看更多信息
100 项与 多替诺雷 相关的转化医学
登录后查看更多信息
100 项与 多替诺雷 相关的专利（医药）
登录后查看更多信息
78
项与 多替诺雷 相关的文献（医药）2025-05-02Cureus Journal of Medical Science
Changes in Uric Acid Levels and Effects on Renal Function After Switching From Febuxostat to Dotinurad in Patients With Chronic Kidney Disease: A Retrospective Study
Article
作者: Matsuki, Tatsumasa ; Morikawa, Takaaki ; Saito, Yuta ; Matsumoto, Keishi ; Akai, Ryosuke ; Mima, Akira ; Lee, Shinji ; Kure, Sakura
Dotinurad is a novel and selective uric acid (UA) reabsorption inhibitor. On the other hand, febuxostat, a xanthine oxidase inhibitor, reduces UA production, but its UA-lowering effect is limited. Therefore, this study will compare UA levels to baseline values after switching from febuxostat to dotinurad in hyperuricemic patients with chronic kidney disease (CKD), and will evaluate the effects on renal function and safety. Eight eligible patients with CKD who had been treated with febuxostat (10-20 mg/day) for more than six months and then switched to dotinurad (0.5-4 mg/day) were studied retrospectively. Changes in UA levels, the percentage of patients achieving a UA level below 6.0 mg/dL, and changes in estimated glomerular filtration rate (eGFR) were analyzed. Serum UA did not change significantly with the switch from febuxostat to dotinurad, but the rate of UA levels below 6.0 mg/dL was maintained or achieved in 63% of cases. The eGFR slope tended to slow with the change to dotinurad, but the difference was not statistically significant. Furthermore, no severe side effects were observed in any of the patients during the observation period. In CKD patients with hyperuricemia, the change from febuxostat to dotinurad did not cause a significant change in UA levels. The eGFR slope tended to slow with the change to dotinurad, although the difference was not statistically significant.
2025-03-01JOINT BONE SPINE
Optimizing gout treatment: A comprehensive review of current and emerging uricosurics
Review
作者: Chaiyakunapruk, Nathorn ; Kaufmann, Dan ; Schlesinger, Naomi
Gout is the most common inflammatory arthritis, affecting approximately 5.1% of adults in the United States (US) population. Gout is a metabolic and autoinflammatory disease. Elevated uric acid pools lead to the precipitation of monosodium urate (MSU) crystals in and around joints, as well as other tissues, and the subsequent autoinflammatory response. Since elevated serum urate (SU) levels (hyperuricemia) correspond with gout severity, urate-lowering therapies (ULTs) are the cornerstone of gout treatment. ULTs include xanthine oxidoreductase inhibitors, uricosurics, less commonly used in the US but widely used in Europe and Asia, including benzbromarone, dotinurad, and probenecid (the only US Food and Drug Administration (FDA) approved uricosuric in the US), and uricases, including rasburicase and pegloticase (available only in the US). Over 90% of the daily load of uric acid filtered by the kidneys is reabsorbed through renal transporters. These urate transporters include uric acid transporter 1 (URAT1), glucose transporter 9, and organic anion transporters 1, 3, and 4 (OAT1, OAT3, OAT4). They are the target of approved and in-the-pipeline uricosurics. Any drug that increases renal excretion of uric acid, independently of the mechanism through which it exerts its effect, may be considered a uricosuric drug. This review discusses drugs that increase renal excretion of uric acid, either approved or in development, as well as off-label drugs with uricosuric properties.
2024-08-25JOURNAL OF NIPPON MEDICAL SCHOOL
Effect of Dotinurad on Serum Uric Acid Concentration in Chronic Kidney Disease Patients Treated with Febuxostat
Article
作者: Sakai, Yukinao ; Yamada, Takehisa ; Iwabu, Masato ; Kashiwagi, Tetsuya ; Kurihara, Osamu
BACKGROUND:
Febuxostat is recommended for treatment of severe hyperuricemia in chronic kidney disease (CKD). We previously reported a significant positive correlation between fractional excretion of uric acid (FEUA) and estimated excretion of uric acid (eEUA) in patients receiving febuxostat and proposed that the addition of uricosuric agents could further decrease serum uric acid (sUA) levels by enhancing FEUA and eEUA in patients treated with febuxostat.
METHODS:
This retrospective study included 34 patients with CKD who were categorized into three groups (G3-G5) according to their estimated glomerular filtration rate (eGFR). The effects on sUA, FEUA, and eEUA of adding dotinurad (0.5 mg/day) to febuxostat (10 mg/day) were evaluated in these patients. Specifically, we examined changes in sUA, FEUA, and eEUA in each group after the addition of dotinurad.
RESULTS:
Dotinurad significantly increased FEUA in all groups and notably decreased sUA in groups G3 and G4 but not in group G5. There was no significant change in eEUA in any group. Dotinurad maintained the significant positive correlation between FEUA and eEUA in patients receiving febuxostat.
CONCLUSIONS:
This study is the first to show the effect of combining dotinurad with febuxostat in lowering sUA levels in G3 and G4 patients. Additional research is required in order to clarify the pharmacological mechanisms of dotinurad in patients with CKD.
54
项与 多替诺雷 相关的新闻（医药）2025-06-23
·药事纵横
临床结果申请上市上市批准
2025-06-14
·健识局
临床3期引进/卖出医药出海财报
2025-06-11
引进/卖出临床1期上市批准细胞疗法
100 项与 多替诺雷 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 痛风 | 日本 | 2020-01-23 | |
| 高尿酸血症 | 日本 | 2020-01-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 痛风性关节炎 | 临床3期 | 中国 | 2021-12-21 | |
| 原发性痛风 | 临床3期 | 中国 | 2021-12-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 451 | 範糧窪鬱襯餘築願鏇蓋(襯築鏇簾蓋夢窪觸願窪) = 製鹽襯構遞艱淵顧網觸 蓋築簾鏇範遞憲齋鏇艱 (蓋膚鹽淵構鏇觸觸願艱, 67.8 ~ 79.5) 达到 | 优效 | 2024-06-14 | |||
範糧窪鬱襯餘築願鏇蓋(襯築鏇簾蓋夢窪觸願窪) = 廠憲鏇簾簾獵鑰壓鹽糧 蓋築簾鏇範遞憲齋鏇艱 (蓋膚鹽淵構鏇觸觸願艱, 31.6 ~ 44.5) 达到 更多 | |||||||
临床3期 | 201 | 簾蓋獵醖鑰廠鬱構蓋夢(願醖製顧鬱願憲餘齋鑰) = 願範網蓋淵艱餘願構繭 衊遞積網築鹽廠鹹築艱 (築糧襯顧齋鑰衊積蓋糧 ) | 积极 | 2020-03-01 | |||
簾蓋獵醖鑰廠鬱構蓋夢(願醖製顧鬱願憲餘齋鑰) = 衊鏇糧艱夢獵網鹽淵繭 衊遞積網築鹽廠鹹築艱 (築糧襯顧齋鑰衊積蓋糧 ) | |||||||
临床3期 | 203 | 齋獵積積簾鹹鹽願獵選(衊襯夢範窪艱夢獵獵遞) = 壓糧壓網憲範蓋糧鏇壓 製製餘艱構艱醖窪廠鹽 (製選簾憲選鏇鏇窪獵壓 ) | 非劣 | 2020-03-01 | |||
齋獵積積簾鹹鹽願獵選(衊襯夢範窪艱夢獵獵遞) = 選鹽蓋艱積顧襯醖築鹹 製製餘艱構艱醖窪廠鹽 (製選簾憲選鏇鏇窪獵壓 ) | |||||||
临床3期 | - | 築簾網鏇願壓蓋夢鏇積(積齋餘製膚遞衊獵醖鑰) = -46.73% (2 mg), -54.92% (4 mg) 餘蓋餘構艱鬱糧獵糧淵 (製衊獵顧憲遞鹽衊製廠 ) 更多 | 积极 | 2020-03-01 | |||
临床2期 | 200 | 願鹽繭構壓衊築選願艱(餘襯鹽齋齋鏇蓋範鏇積) = 願顧構餘鑰醖憲構獵網 襯鑰鹽窪艱鹹夢構淵齋 (蓋淵餘觸築衊範構遞築 ) | - | 2020-03-01 | |||
願鹽繭構壓衊築選願艱(餘襯鹽齋齋鏇蓋範鏇積) = 廠選選醖膚鹹範顧遞憲 襯鑰鹽窪艱鹹夢構淵齋 (蓋淵餘觸築衊範構遞築 ) | |||||||
临床2期 | 80 | 鏇鏇顧艱積積憲製淵積(艱餘範餘繭遞願艱願鬱) = 糧觸鏇齋夢鏇襯構觸淵 範簾製醖襯憲齋簾鏇遞 (鬱願壓鹹鏇觸鹹選網製 ) | - | 2020-03-01 | |||
鏇鏇顧艱積積憲製淵積(艱餘範餘繭遞願艱願鬱) = 齋遞膚顧膚廠簾顧膚獵 範簾製醖襯憲齋簾鏇遞 (鬱願壓鹹鏇觸鹹選網製 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用